Riskpilot← Back to searchSign inGet full accessAPORANA AS
ASActiveOrg 983141838Fridtjof Nansens Gate 21, 8622 Mo I RanaRetail sale of pharmaceutical products · NACE 4773Est. 200131 employees
Revenue 2025
NOK 89,4M
+7% vs 2024
EBITDA margin
4.8%
-21% vs 2024
Equity ratio
22.3%
Financial strength
Net profit 2025
NOK 3,4M
-20% vs 2024
| Revenue | NOK 89,4M | +7% |
| EBITDA | NOK 4,3M | -21% |
| Net profit | NOK 3,4M | -20% |
| Total assets | NOK 16,2M | -7% |
| Equity | NOK 3,6M | +2103% |
| Employees | 31 | — |
Legal name
APORANA AS
Org number
983141838
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
14. mars 2001
Share capital
NOK 164 000
Employees
31 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Eie og drift av apotek.
Address
Fridtjof Nansens Gate 21, 8622 Mo I Rana
Phone
+4775143140
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 65 291 | 68 354 | 72 590 | 83 568 | 89 433 |
| Staff expenses | −12 477 | −13 030 | −13 438 | −15 145 | −17 555 |
| EBITDA | 3 449 | 3 415 | 4 262 | 5 507 | 4 327 |
| Depreciation & amort. | −273 | −291 | −241 | −226 | −196 |
| EBIT | 3 176 | 3 124 | 4 021 | 5 281 | 4 131 |
| Net financials | −9 | 8 | 116 | 249 | 291 |
| Profit before tax | 3 167 | 3 131 | 4 136 | 5 529 | 4 423 |
| Tax | 697 | 704 | 911 | 1 217 | 973 |
| Net profit | 2 470 | 2 427 | 3 226 | 4 312 | 3 450 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 13 760 | 14 036 | 19 787 | 17 466 | 16 207 |
| Equity | 165 | 165 | 164 | 164 | 3 614 |
| Long-term debt | 60 | 46 | 34 | 32 | 0 |
| Short-term debt | 13 536 | 13 825 | 19 589 | 17 269 | 12 561 |
| Total debt | 13 596 | 13 871 | 19 623 | 17 302 | 12 593 |
EBITDA margin
4.8%
This company
15.8%
Market median
-70% vs market
20212025
Equity ratio
22.3%
This company
38.2%
Market median
-42% vs market
20212025
Return on equity
95.5%
This company
18.4%
Market median
+419% vs market
20212025
Net profit margin
3.9%
This company
8.1%
Market median
-52% vs market
20212025
Asset turnover
5.52×
This company
1.12×
Market median
+393% vs market
20212025
Debt / equity
3.49×
This company
0.62×
Market median
-463% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2026 | |
| Chairman | 2026 | |
| Chairman | 2023 | |
| Board of Directors | 2023 | |
| Former (1) | ||
| Board of Directors | 2002 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 49.39% | 49.39% | 2024 | |
| Individual | 21.95% | 21.95% | 2024 | |
| Company | 15.85% | 15.85% | 2024 | |
| Individual | 12.8% | 12.8% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of APORANA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Terje Kvaal | Board of Directors | 0 companies |
| Michael Roland Ecker | Chairman | 0 companies |
| Kari Mette Dahl | Chairman | 0 companies |
| Hanne Aasberg | Board of Directors | 0 companies |
| Jan Erik Helgemo | Board of Directors | 0 companies |